<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02700555</url>
  </required_header>
  <id_info>
    <org_study_id>CA02</org_study_id>
    <nct_id>NCT02700555</nct_id>
  </id_info>
  <brief_title>Surveillance of Metabolic Parameters in Patients With Colorectal Cancer</brief_title>
  <acronym>SPRING</acronym>
  <official_title>Surveillance of Metabolic Parameters in Patients Who Will Receive Chemotherapy After Surgical Resection of Colorectal Cancer: KBSMC Colon Cancer Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kangbuk Samsung Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kangbuk Samsung Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, single center, cohort study for surveillance of metabolic parameters in
      patients who will receive chemotherapy after surgical resection of colorectal cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective - Incidence of newly developed diabetes mellitus in patients with
      colorectal cancer after post-operative chemotherapy

      Secondary objective - Pre-operative incidence of diabetes and characteristics of metabolic
      parameters of patients with colorectal cancer; Incidence of developed poorly controlled
      glucose level in diabetic patients with colorectal cancer after post-operative chemotherapy;
      3-year recurrence-free survival according to status of diabetes and metabolic parameters;
      5-year recurrence-free survival according to status of diabetes and metabolic parameters
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>60 Months</target_duration>
  <primary_outcome>
    <measure>Incidence of newly developed diabetes mellitus</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Incidence of newly developed diabetes mellitus in patients with colorectal cancer after post-operative chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-operative incidence of diabetes</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Pre-operative incidence of diabetes (&gt; 6.5% of HbA1c) and abnormal metabolic parameters (&gt; 23 kg/m2 of BMI or dyslipidemia) of patients with colorectal cancer;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of developed poorly controlled glucose level</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Incidence of developed poorly controlled glucose level in diabetic patients with colorectal cancer after post-operative chemotherapy;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year recurrence-free survival &amp; 5-year recurrence-free survival</measure>
    <time_frame>up to 36-60 months</time_frame>
    <description>3-year and 5-year recurrence-free survival according to status of diabetes (&gt; 6.5% of HbA1c) and abnormal metabolic parameters (&gt; 23 kg/m2 of BMI or dyslipidemia)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Colorectal Cancer</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who will receive chemotherapy after surgical resection of colorectal cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Who will get surgical resection for colorectal cancer

          -  Who has diagnosed with diabetes

          -  Who met the criteria for testing of diabetes in asymptomatic adult individuals

          -  Criteria for testing for diabetes in asymptomatic adult individuals

               -  overweight (BMI&gt;25 kg/m2*) and have additional risk factors (physical inactivity,
                  first-degree relative with diabetes, high-risk race/ethnicity (e.g., African
                  American, Latino, Native American, Asian American, Pacific Islander), women who
                  delivered a baby weighing 0.9 lb or were diagnosed with GDM, hypertension
                  (&gt;140/90 mmHg or on therapy for hypertension), HDL cholesterol level ,35 mg/dL
                  (0.90 mmol/L) and/or a triglyceride level &gt;250 mg/dL (2.82 mmol/L), women with
                  polycystic ovarian syndrome, HbA1C &gt;5.7%, IGT, or IFG on previous testing, other
                  clinical conditions associated with insulin resistance (e.g., severe obesity,
                  acanthosis nigricans), history of CVD)

        Exclusion Criteria:

          -  Previously exposed to surgery or chemotherapy for colorectal cancer

          -  Second primary malignancy (except in situ carcinoma of the cervix or adequately
             treated basal cell carcinoma of the skin or prior malignancy treated more than 5 years
             ago without recurrence

          -  Presence of CNS metastasis

          -  Not able or willing to give informed consent

          -  Any patients judged by the investigator to be unfit to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Hoe Koo, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong-Hoe Koo, MD,PhD</last_name>
    <phone>+82-2001-8330</phone>
    <email>d.h.koo@samsung.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cheol-Young Park, MD,PhD</last_name>
    <phone>+82-2001-8330</phone>
    <email>cyber.park@samsung.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-746</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Hoe Koo, MD,PhD</last_name>
      <phone>+82-2-2001-8330</phone>
      <email>d.h.koo@samsung.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009 Nov;22(4):191-7. doi: 10.1055/s-0029-1242458.</citation>
    <PMID>21037809</PMID>
  </reference>
  <reference>
    <citation>Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB 3rd, Fuchs CS. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003 Feb 1;21(3):433-40.</citation>
    <PMID>12560431</PMID>
  </reference>
  <reference>
    <citation>Mills KT, Bellows CF, Hoffman AE, Kelly TN, Gagliardi G. Diabetes mellitus and colorectal cancer prognosis: a meta-analysis. Dis Colon Rectum. 2013 Nov;56(11):1304-19. doi: 10.1097/DCR.0b013e3182a479f9. Review.</citation>
    <PMID>24105007</PMID>
  </reference>
  <reference>
    <citation>Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol. 2015 Jun 1;33(16):1787-96. doi: 10.1200/JCO.2014.60.0213. Epub 2015 Apr 27. Review.</citation>
    <PMID>25918287</PMID>
  </reference>
  <reference>
    <citation>Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev. 2014 Feb;30(2):96-102. doi: 10.1002/dmrr.2486. Review.</citation>
    <PMID>24123849</PMID>
  </reference>
  <reference>
    <citation>Feng JP, Yuan XL, Li M, Fang J, Xie T, Zhou Y, Zhu YM, Luo M, Lin M, Ye DW. Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: results from a single-centre cohort study. Colorectal Dis. 2013 Jan;15(1):27-33. doi: 10.1111/j.1463-1318.2012.03097.x.</citation>
    <PMID>22594556</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. 2014 Jan;37 Suppl 1:S14-80. doi: 10.2337/dc14-S014.</citation>
    <PMID>24357209</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2016</study_first_submitted>
  <study_first_submitted_qc>March 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2016</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kangbuk Samsung Hospital</investigator_affiliation>
    <investigator_full_name>Dong-Hoe Koo</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>diabetes</keyword>
  <keyword>metabolic parameters</keyword>
  <keyword>Surveillance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

